HC Royalty Inks Hefty Deals to Propel Nuron and Raptor
HealthCare Royalty Partners II LP closed an $80 million financing with Nuron Biotech Inc. that included a $30 million equity investment and a $50 million synthetic royalty agreement linked to future sales of Meningitec and its HibTiter vaccine (Haemophilus b conjugate vaccine [diphtheria CRM197 protein conjugate]).
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST